Gracell Biotechnologies Inc reports results for the quarter ended in March - Earnings Summary

Gracell Biotechnologies

15/05/2023 14:32

* Gracell Biotechnologies Inc  GRCL.OQ  reported a quarterly
adjusted loss of 35 cents​​ per share for the quarter ended in
March. The mean expectation of six analysts for the quarter was
for a loss of 39 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Gracell Biotechnologies Inc's reported EPS for the quarter
was a
loss of 35 cents​.
    * The mean earnings estimate of analysts had fallen by
about 36.2%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Gracell Biotechnologies Inc shares had risen by 9.7% this
quarter and lost 11.3% so far this year.
    * The company reported a quarterly loss of $22.09 million.
    * Wall Street's median 12-month price target for Gracell
Biotechnologies Inc is $12.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data May
15 at 01:32 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2023      -0.39          -0.35          Beat
 Dec. 31 2022      -0.21          -0.30          Missed
 Sep. 30 2022      -0.15          -0.35          Missed
 Jun. 30 2022      -0.08          -0.30          Missed